Brain stimulation test as a marker of thinking decline in Parkinson's
Tests a magnetic brain stimulation measure in adults with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: TMS-related Measures as Biomarker of Cognitive Impairment in PD
Key facts
- Where
- Sterzing, Trento, and Trieste, ItalySee the 3 sites
Where in Italy
- UOC Neuroriabilitazione - Azienda Sanitaria dell'Alto AdigeSterzing, ItalyNot yet recruiting
- UOC Neurologia - Azienda Provinciale per i Servizi Sanitari (APSS)Trento, ItalyTaking people
- SC Clinica Neurologica - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI)Trieste, ItalyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Azienda Sanitaria Universitaria Integrata del Trentino
- Trial code
- NCT06835595
- Record updated
- 22 December 2025
- Original description
The goal of the present study is to explore the diagnostic and prognostic value of neurophysiological biomarkers obtained through paired-pulse Transcranial Magnetic Stimulation (TMS) techniques in individuals affected by Parkinson's disease (PD) with and without cognitive decline.Read full original descriptionShow less
Transcranial Magnetic Stimulation (TMS) Related Measures as Biomarker of Cognitive Impairment in Parkinson's Disease (PD)
The goal of the present study is to explore the diagnostic and prognostic value of neurophysiological biomarkers obtained through paired-pulse Transcranial Magnetic Stimulation (TMS) techniques in individuals affected by Parkinson's disease (PD) with and without cognitive decline.
The main questions it aims to answer are:
* TMS measures of cortical excitability are able to distinguish between PD patients cognitively normal, PD-Mild Cognitive Impairment (PD-MCI) and PD-Dementia (PD-D)? * TMS measures of cortical excitability are able to predict progression of PD patient cognitive status from cognitively normal to PD-MCI and PD-D?
Inclusion: Age > 18 years; Ability to undergo an extensive neuropsychological evaluation; Ability to sign informed consent for the study; Diagnosed with idiopathic PD according to the latest revision of the MDS criteria; On stable and optimal antiparkinsonian therapy for at least four weeks.
Exclusion: Presence of a cochlear implant, ferromagnetic brain device or near the site of brain stimulation, pacemaker, brain electrodes for DBS, electromechanical devices with IPG, or any other implantable stimulator, including peripheral ones; Treatment with anticholinesterase drugs, benzodiazepines, neuroleptics, anticholinergics, or antidepressants in the last month; Treatment with drugs that lower the seizure threshold (e.g., imipramine, amitriptyline, doxepin, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, MDMA, ecstasy, phencyclidine, ketamine, gamma-hydroxybutyrate, alcohol, theophylline); Active cochlear pathology (especially if currently receiving ototoxic drugs, such as aminoglycoside antibiotics); Systemic diseases of significant severity, including cardiovascular and cerebrovascular conditions (e.g., active neoplasms requiring chemotherapy, or end-stage heart failure); Presence of any active neurological disease, in addition to PD; History of epilepsy; History of cerebrovascular, tumor-related, infectious, or metabolic brain conditions predisposing to seizures or causing symptomatic epilepsy; Dementia according to the latest revision of the MDS criteria for PDD; Pregnancy or breastfeeding; Alcoholism.